These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 18477967)

  • 21. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():15-21. PubMed ID: 18307645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy.
    Yamamoto T; Umegae S; Matsumoto K
    Dig Liver Dis; 2011 May; 43(5):386-90. PubMed ID: 21195041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.
    Bossa F; Latiano A; Rossi L; Magnani M; Palmieri O; Dallapiccola B; Serafini S; Damonte G; De Santo E; Andriulli A; Annese V
    Am J Gastroenterol; 2008 Oct; 103(10):2509-16. PubMed ID: 18721243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ulcerative colitis: current medical therapy and strategies for improving medication adherence.
    Zhang Z; Kennedy H
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):1-8. PubMed ID: 19011573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment.
    Bresci G; Parisi G; Capria A
    Colorectal Dis; 2008 Oct; 10(8):814-7. PubMed ID: 18834420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-daily mesalamine granules for ulcerative colitis.
    Lawlor G; Ahmed A; Moss AC
    Expert Rev Clin Immunol; 2010 Jul; 6(4):521-6. PubMed ID: 20594123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
    Fallingborg JF
    Ugeskr Laeger; 2006 May; 168(21):2049-51. PubMed ID: 16768921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.
    Frieri G; Pimpo M; Galletti B; Palumbo G; Corrao G; Latella G; Chiaramonte M; Caprilli R
    Dig Liver Dis; 2005 Feb; 37(2):92-6. PubMed ID: 15733520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
    Folwaczny C
    Z Gastroenterol; 2000 Jun; 38(6):547-50. PubMed ID: 10923365
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of ulcerative colitis.
    Ludwig D; Stange EF
    Hepatogastroenterology; 2000; 47(31):83-9. PubMed ID: 10690588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.
    Cohen RD
    Aliment Pharmacol Ther; 2006 Aug; 24(3):465-74. PubMed ID: 16886912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.
    George J; Present DH; Pou R; Bodian C; Rubin PH
    Am J Gastroenterol; 1996 Sep; 91(9):1711-4. PubMed ID: 8792685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis.
    Lee HJ; Jung ES; Lee JH; Hong SP; Kim TI; Kim WH; Cheon JH
    Hepatogastroenterology; 2012; 59(117):1415-20. PubMed ID: 22683958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.